| Identification | Back Directory | [Name]
LB-80317 | [CAS]
441785-24-6 | [Synonyms]
LB-80317
Tegoprazan
[[[1-[(2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl]cyclopropyl]oxy]methyl]phosphonic acid
Phosphonic acid, P-[[[1-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl]cyclopropyl]oxy]methyl]- | [Molecular Formula]
C10H14N5O5P | [MDL Number]
MFCD34469159 | [MOL File]
441785-24-6.mol | [Molecular Weight]
315.22 |
| Hazard Information | Back Directory | [Uses]
LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC50 of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment[1][2]. | [in vivo]
Forty percent of the amount of LB80331/LB80317 in the mouse liver is detected as the phosphorylated form. LB80380 is rapidly absorbed and converted to LB80331. LB80317 has a long half-life at steady-state (T1/2=8.3-9.9 hours)[1]. | [References]
[1] Man-Fung Yuen, et al. Pharmacokinetics of LB80331 and LB80317 Following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. Antimicrob Agents Chemother. 2009 May;53(5):177 DOI:10.1128/AAC.01290-08
[2] Lung-Yi Mak, et al. Pharmacokinetic Evaluation of Besifovir for the Treatment of HBV Infection. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):101-106. DOI:10.1080/17425255.2018.1417983 |
|
|